Metosyn FAPG Cream

Active Ingredient

Fluocinonide USP 0.050% w/w

Cream for topical administration

Metosyn is suitable for treating a wide variety of inflammatory, pruritic and allergic disorders of the skin. It is indicated for topical application in the following conditions:

Eczema and dermatitis; atopic eczema, seborrhoeic dermatitis, discoid eczema, contact dermatitis, neuro-dermatitis, prurigo, psoriasis (excluding widespread plaque psoriasis), lichen planus, discoid lupus erythematosus.

Metosyn FAPG cream may be used for wet or dry lesions.

Adults

A small quantity of Metosyn' FAPG cream should be applied three to four times daily to the affected area and massaged well in.

Once improvement is apparent, usage may be reduced to twice or even once daily.

Children

Under one year: Metosyn preparations are not advised in the treatment of children under one year of age.

Over one year: As adult dose, however, it is recommended that treatment should not normally be extended beyond five days and occlusion in such cases should not be used.

Elderly

As adult dose.

It is recommended that Metosyn is used undiluted.

Metosyn is contraindicated in rosacea, acne and peri-oral dermatitis. As with all topical steroids, Metosyn is contraindicated in tuberculous, syphilitic, fungal and viral infections of the skin. The product should not be used for napkin eruption or anogenital pruritus.

Long-term continuous topical steroid therapy can produce atrophic skin changes and dilation of the superficial blood vessels particularly when occlusive dressings are used or where skin folds are involved. Prolonged use of topical steroids or treatment of extensive areas, even without occlusion, can result in sufficient absorption of the steroid to produce the features of hypercorticalism and underlying adrenal suppression, especially in infants and children.

It is recommended that treatment on the face should not normally be extended beyond 5 days, and occlusion in such cases should not be used.

Where there is bacterial infection associated with an inflammatory skin condition, Metosyn should only be administered if adequate antibacterial cover is also given.

When using topical steroids to treat psoriasis there are risks of rebound relapse following the development of tolerance, and of generalised pustular psoriasis. Impairment of the barrier function of the skin may lead to local and systemic toxicity. Careful patient supervision is important.

Treatment should be discontinued if unfavourable reactions are seen.

Absorption is greatest where the skin is thin or raw.

None known

Pregnancy: There is inadequate evidence of safety in human pregnancy. Topical administration of steroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intrauterine growth retardation. There may therefore be a very small risk of such effects on the human foetus.

Lactation: Topical steroids should not be applied to the breasts prior to nursing. When topical steroid treatment is considered necessary for other parts of the body, both the amount applied and the length of treatment should be minimised.

No precautions are necessary.

With Metosyn side effects are extremely rare but, as with all topical steroids, the occasional patient may show an adverse reaction such as hypersensitivity. Irritation at the site of application may occur infrequently. Extensive treatment, particularly involving occlusive dressings or where skin folds are involved, can result in both local atrophic changes, such as striae, skin thinning and telangiectasia, and systemic effects such as adrenal suppression.

The use of topical steroids on infected lesions, without the addition of appropriate anti-infective therapy, can result in the spread of opportunist infection.

The eyes should be avoided.

Local side effects include contact dermatitis, perioral dermatitis, acne, or worsening of acne or acne rosacea, mild depigmentation which may be reversible and hypertrichosis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system in the United Kingdom: Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Overdose (Symptoms, Emergency Procedures, Antidotes)

A 25g tube of Metosyn FAPG cream contains 12.5mg of fluocinonide. Toxic effects are not likely to occur following accidental ingestion. Similarly, the components of the vehicle, singly or collectively, have not been shown to produce toxic effects in these quantities.

Fluocinonide is a synthetic anti-inflammatory corticosteroid. Its mechanisms of action are related to vasoconstriction and suppression of membrane permeability, mitotic activity, the immune response and release of inflammatory mediators.

The extent of percutaneous absorption of fluocinonide is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Following absorption, fluocinonide is metabolised primarily in the liver and excreted by the kidneys.

Fluocinonide is a drug on which extensive clinical experience has been obtained. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.

Citric Acid Ph Eur

1,2,6 Hexanetriol HSE

Polyethylene Glycol USNF

Stearyl Alcohol USP

Propylene Glycol Ph Eur

None Known

3 years

Store below 30°C.

Unlacquered, latex banded, collapsible aluminium tubes, in pack sizes of 25g and 100g.

Use undiluted, as instructed by the prescriber.

Reig Jofre UK Limited

Unit 9A Caddsdown Business Support Centre

Caddsdown Industrial Park

Bideford

Devon

EX39 3DX

United Kingdom

PL 44095/0014

03/02/1989 / 08/12/2008

29/03/2019